Clinical Trial Update: SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms [Phase 3]

View source ↗

Summary

Phase 3 trial update for SPD503 (guanfacine hydrochloride) in ADHD with oppositional symptoms; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• SPD503

Snippet

Sponsor: Shire | Conditions: ADHD | Phase 3 | Status: COMPLETED | Results posted: 2009-11-26